Genomic discovery of EF-24 targets unveils antitumorigenic mechanisms in leukemia cells.

ABSTRACT: Curcumin, a polyphenolic compound derived from the plant Curcuma longa L., has demonstrated a wide range of therapeutic properties, including potential anticancer effects. However, its clinical efficacy is limited due to poor bioavailability and stability. To overcome these challenges, curcumin analogs like EF-24 have been developed with improved pharmacological properties. In this study, in order to improve our understanding of EF-24's potential mechanisms of action, we used whole-transcriptome sequencing to identify genome-wide functional impacts of EF-24 treatment in leukemia cells. These results enabled the development of a testable model system for associating druggable genes with clinical disease targets related to EF-24 treatment. To develop our model of the transcriptional response

SUBMITTER: Singh AP 

PROVIDER: S-EPMC12456773 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature